{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:02:57Z","timestamp":1792807377404,"version":"4.5.0"},"reference-count":154,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>New technological platforms, such as mRNA and adenoviral vector vaccines, have been utilized to develop coronavirus disease 2019 (COVID-19) vaccines. These new modalities enable rapid and flexible vaccine design and cost-effective and swift manufacturing, effectively combating pandemics caused by mutating viruses. Innovation ecosystems, including universities, startups, investors, and governments are crucial for developing these cutting-edge technologies. This review summarizes the research and development trajectory of these vaccine technologies, their investments, and the support surrounding them, in addition to the technological details of each technology. In addition, this study examines the importance of an innovation ecosystem in developing novel technologies, comparing it with the case of Japan, which has lagged behind in COVID-19 vaccine development. It also explores the direction of vaccine development in the post-COVID-19 era.<\/jats:p>","DOI":"10.3390\/vaccines11121737","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:24:13Z","timestamp":1700562253000},"page":"1737","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-7741","authenticated-orcid":false,"given":"Ryo","family":"Okuyama","sequence":"first","affiliation":[{"name":"College of International Management, Ritsumeikan Asia Pacific University, Beppu 874-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","article-title":"RNA therapeutics: Updates and future potential","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2338","DOI":"10.1002\/rmv.2338","article-title":"Human adenovirus type 26 basic biology and its usage as vaccine vector","volume":"32","author":"Majhen","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2021). COVID-19: Characteristics and Therapeutics. Cells, 10.","DOI":"10.3390\/cells10020206"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ma, L., Li, H., Lan, J., Hao, X., Liu, H., Wang, X., and Huang, Y. (2021). Comprehensive analyses of bioinformatics applications in the fight against COVID-19 pandemic. Comput. Biol. Chem., 95.","DOI":"10.1016\/j.compbiolchem.2021.107599"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: Construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: History and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"19","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Okuyama, R. (2022). Nurturing deep tech to solve social problems: Learning from COVID-19 mRNA vaccine development. Pathogens, 11.","DOI":"10.3390\/pathogens11121469"},{"key":"ref_13","unstructured":"(2023, September 12). Development of the ChAdOx Vaccine Platform. Available online: https:\/\/www.jenner.ac.uk\/about\/the-oxford-astrazeneca-covid-19-vaccine\/ChAdOx-platform."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ajic.2022.01.026","article-title":"The long road of pandemic vaccine development to rollout: A systematic review on the lessons learnt from the 2009 H1N1 influenza pandemic","volume":"50","author":"Ankomah","year":"2022","journal-title":"Am. J. Infect. Control"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbiomolbio.2023.02.004","article-title":"An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines","volume":"178","author":"Bayani","year":"2023","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vartak, A., and Sucheck, S.J. (2016). Recent Advances in Subunit Vaccine Carriers. Vaccines, 4.","DOI":"10.3390\/vaccines4020012"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kheirvari, M., Liu, H., and Tumban, E. (2023). Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses, 15.","DOI":"10.3390\/v15051109"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e127042","DOI":"10.5812\/ijpr-127042","article-title":"A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases","volume":"21","author":"Sharifzadeh","year":"2022","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/2051013615613272","article-title":"Plant-based vaccines for animals and humans: Recent advances in technology and clinical trials","volume":"3","author":"Takeyama","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108162","DOI":"10.1016\/j.intimp.2021.108162","article-title":"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines","volume":"100","author":"Ghasemiyeh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2154100","DOI":"10.1080\/21645515.2022.2154100","article-title":"Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication","volume":"18","author":"Kumar","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like particle vaccines: Immunology and formulation for clinical translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.14740\/jocmr4490","article-title":"Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use","volume":"13","author":"Vasireddy","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs","volume":"119","author":"Joe","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1389201013378815","article-title":"Genetically modified viruses: Vaccines by design","volume":"2","author":"Stephenson","year":"2001","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_32","unstructured":"(2023, September 12). Moderna Announces First Participant Dosed in NIH-Led Phase 1 Study of mRNA Vaccine (mRNA-1273) against Novel Coronavirus. Available online: https:\/\/www.businesswire.com\/news\/home\/20200316005666\/en\/Moderna-Announces-First-Participant-Dosed-in-NIH-led-Phase-1-Study-of-mRNA-Vaccine-mRNA-1273-Against-Novel-Coronavirus."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1130539","DOI":"10.3389\/fimmu.2023.1130539","article-title":"SARS-CoV-2 Omicron variants: Burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines","volume":"14","author":"Pather","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","unstructured":"(2023, September 14). NIKKEI. Available online: https:\/\/www.nikkei.com\/article\/DGKKZO60565180W2A500C2TB0000\/."},{"key":"ref_36","unstructured":"(2023, September 14). Japanese Science and Technology Indicators 2022. Available online: https:\/\/www.nistep.go.jp\/research\/science-and-technology-indicators-and-scientometrics\/indicators."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Okuyama, R. (2023). Academia\u2019s contribution to drug discovery: Current status and perspectives in Japan. Translat. Regulat. Sci., 5, in press.","DOI":"10.33611\/trs.2023-005"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5\u2032-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Muramatsu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","article-title":"The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system","volume":"32","author":"Bernard","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_48","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3\u2032-O-methyl)GpppG and 7-methyl (3\u2032-deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e202200005","DOI":"10.1002\/tcr.202200005","article-title":"Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines","volume":"22","author":"Shanmugasundaram","year":"2022","journal-title":"Chem. Rec."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell Toxicol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kudla, G., Lipinski, L., Caffin, F., Helwak, A., and Zylicz, M. (2006). High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol., 4.","DOI":"10.1371\/journal.pbio.0040180"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC purification of in vitro transcribed long RNA","volume":"969","author":"Weissman","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Boros","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/nar\/gkl1165","article-title":"Quantitative and mechanism-based investigation of post-nuclear delivery events between adenovirus and lipoplex","volume":"35","author":"Hama","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1038\/s41598-017-07246-0","article-title":"Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria","volume":"7","author":"Milicic","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.-G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9.","DOI":"10.3390\/vaccines9121490"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QCO.0000000000000936","article-title":"Sequence-based diagnostics and precision medicine in bacterial and viral infections: From bench to bedside","volume":"36","author":"Pham","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2023). Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. Viruses, 15.","DOI":"10.3390\/v15030698"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1089\/hum.2005.16.1014","article-title":"Gendicine: The first commercial gene therapy product","volume":"16","author":"Wilson","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonga","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Dicks, M.D., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V., and Cottingham, M.G. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-020-00221-3","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","volume":"5","author":"Graham","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","first-page":"433","article-title":"Adenovirus region E3 proteins that prevent cytolysis by cytotoxic T cells and tumor necrosis factor","volume":"6","author":"Wold","year":"1989","journal-title":"Mol. Biol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Pereira, I.R., Vilar-Pereira, G., Marques, V., da Silva, A.A., Caetano, B., Moreira, O.C., Machado, A.V., Bruna-Romero, O., Rodrigues, M.M., and Gazzinelli, R.T. (2015). A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004594"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"Barough","year":"2008","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk\/benefit assessment","volume":"39","author":"Custers","year":"2021","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.18632\/aging.204299","article-title":"Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients","volume":"14","author":"Pingitore","year":"2022","journal-title":"Aging"},{"key":"ref_91","first-page":"5","article-title":"The \u2018National System of Innovation\u2019 in historical perspective","volume":"19","author":"Freeman","year":"1995","journal-title":"Camb. J. Econ."},{"key":"ref_92","unstructured":"(2023, October 04). An Interview with Dr. Derrick Rossi, Co-Founder of Moderna Therapeutics. Available online: http:\/\/www.simplyblood.org\/2021\/03\/an-interview-with-dr-derrick-rossi-co.html."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.stem.2010.08.012","article-title":"Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA","volume":"7","author":"Warren","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_94","unstructured":"(2023, October 04). Person of the Year 2010. Available online: https:\/\/content.time.com\/time\/specials\/packages\/article\/0,28804,2036683_2036767_2037437,00.html."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/522026a","article-title":"Business: The billion-dollar biotech","volume":"522","author":"Dolgin","year":"2015","journal-title":"Nature"},{"key":"ref_96","unstructured":"(2023, October 04). Flagship Pioneering, HP. Available online: https:\/\/www.flagshippioneering.com\/people\/noubar-afeyan\/."},{"key":"ref_97","unstructured":"(2023, October 04). Interview: Moderna Co-founder Robert Ranger. Available online: https:\/\/www.theguardian.com\/society\/2022\/mar\/12\/moderna-co-founder-robert-langer-covid-19-coronavirus-interview."},{"key":"ref_98","unstructured":"(2023, October 06). AstraZeneca Press Release. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2013\/astrazeneca-moderna-therapeutics-cardiometabolic-diseases-cancer-treatment-21032013.html#."},{"key":"ref_99","unstructured":"(2023, October 06). Alexion Press Release. Available online: https:\/\/media.alexion.com\/news-releases\/news-release-details\/alexion-pharmaceuticals-and-moderna-therapeutics-announce."},{"key":"ref_100","unstructured":"(2023, October 06). Merck Press Release. Available online: https:\/\/www.merck.com\/news\/merck-and-moderna-announce-strategic-collaboration-to-advance-novel-mrna-based-personalized-cancer-vaccines-with-keytruda-pembrolizumab-for-the-treatment-of-multiple-types-of-cancer\/."},{"key":"ref_101","unstructured":"(2023, October 06). Merck Press Release. Available online: https:\/\/www.merck.com\/news\/moderna-and-merck-expand-mrna-cancer-vaccines-collaboration\/."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nbt0613-476","article-title":"AstraZeneca juggernaut heads for Cambridge","volume":"31","author":"Moran","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_103","unstructured":"(2023, October 06). Moderna Homepage. Available online: https:\/\/www.modernatx.com\/partnerships\/strategic-collaborators."},{"key":"ref_104","unstructured":"(2021). Moderna feud with NIH over COVID vaccine. Nat. Biotechnol., 39."},{"key":"ref_105","unstructured":"(2023, October 06). NIAID News Release, Available online: https:\/\/www.niaid.nih.gov\/news-events\/statement-nih-and-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine."},{"key":"ref_106","unstructured":"(2023, October 06). New York Times. 23 February 2023. Available online: https:\/\/www.nytimes.com\/2023\/02\/23\/science\/moderna-covid-vaccine-patent-nih.html."},{"key":"ref_107","unstructured":"(2023, October 07). Moderna Homepage. Available online: https:\/\/www.modernatx.com\/power-of-mrna\/modernas-mrna-platform."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","unstructured":"(2023, August 15). The Woman Developing the Next Generation of Cancer Immunotherapy. Available online: https:\/\/www.labiotech.eu\/interview\/ozlem-tureci-cancer-immunotherapy."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"Schlitter","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Al-Batran, S.E., Schuler, M.H., Zvirbule, Z., Manikhas, G., Lordick, F., Rusyn, A., Vynnyk, Y., Vynnychenko, I., Fadeeva, N., and Nechaeva, M. (2016). FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. J. Clin. Oncol., 34.","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA4001"},{"key":"ref_112","unstructured":"(2017). Ganymed\u2019s Claudin win. Nat. Biotechnol., 35."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14760584.2015.1000871","article-title":"The messenger\u2019s great message for vaccination","volume":"14","author":"Pascolo","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_115","unstructured":"Orosz, M. (Forbes, 2020). German Billionaire Thomas Struengmann Says a Coronavirus Vaccine from His Biotech Firm Would Be a Dream Come True, Forbes."},{"key":"ref_116","unstructured":"(2023, October 07). BioNTech Homepage. Available online: https:\/\/www.biontech.com\/int\/en\/home\/about\/who-we-are\/history.html."},{"key":"ref_117","unstructured":"(2023, October 07). Pfizer Press Release. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/biontech-signs-collaboration-agreement-pfizer-develop-mrna."},{"key":"ref_118","unstructured":"(The Washington Post, 2020). Their Coronavirus Vaccine Candidate Has Made Them Billionaires. This Modest German Turkish Couple Doesn\u2019t Own a Car, The Washington Post."},{"key":"ref_119","unstructured":"(2023, October 08). COVID-19 and Cancer Vaccines with Immunotherapy Pioneers Ugur \u015eahin and \u00d6zlem T\u00fcreci. Available online: https:\/\/www.cancerresearch.org\/blog\/december-2021\/mrna-covid-cancer-vaccines-ugur-sahin-ozlem-tureci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e2119757118","DOI":"10.1073\/pnas.2119757118","article-title":"QnAs with Katalin Karik\u00f3","volume":"118","author":"Nair","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e155559","DOI":"10.1172\/JCI155559","article-title":"A conversation with Katalin Karik\u00f3","volume":"131","author":"Neill","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector","volume":"205","author":"Duncan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1016\/j.vaccine.2022.06.008","article-title":"Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk\/benefit assessment","volume":"40","author":"Folegatti","year":"2022","journal-title":"Vaccine"},{"key":"ref_125","unstructured":"(2023, October 08). The Jenner Institute Press Release. Available online: https:\/\/www.jenner.ac.uk\/about\/newsletter\/jenner-institute-newsletter-autumn-2016\/vaccitech-spin-out-kick-starts-with-ps10m-from-oxford-sciences-innovation."},{"key":"ref_126","unstructured":"(2023, October 08). Vaccitech Homepage. Available online: https:\/\/www.vactitech.co.uk\/about\/."},{"key":"ref_127","unstructured":"(2023, October 08). Oxford University Innovation Press Release. Available online: https:\/\/innovation.ox.ac.uk\/news\/vaccitech-20m-series-a\/."},{"key":"ref_128","unstructured":"(2023, October 08). Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs through Phase 2 Results. Bloomberg 17 March 2021. Available online: https:\/\/www.bloomberg.com\/press-releases\/2021-03-17\/vaccitech-completes-168-million-series-b-financing-to-advance-three-clinical-programs-through-phase-2-results."},{"key":"ref_129","unstructured":"UK Research and Innovation (2023, October 09). The Story behind the Oxford-AstraZeneca COVID-19 Vaccine Success, Available online: https:\/\/www.ukri.org\/news-and-events\/tackling-the-impact-of-covid-19\/vaccines-and-treatments\/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success\/."},{"key":"ref_130","unstructured":"(2023, October 09). ChAdOx1: More than a Coronavirus Vaccine. Available online: https:\/\/www.nature.com\/articles\/d42473-021-00625-2."},{"key":"ref_131","unstructured":"IQVIA (2023, October 09). The Global Use of Medicines 2022. Available online: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/publications\/the-global-use-of-medicines-2022.pdf."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nrd3251","article-title":"The importance of new companies for drug discovery: Origins of a decade of new drugs","volume":"9","author":"Kneller","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Okuyama, R. (2023). Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071794"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1248\/bpb.b23-00107","article-title":"Strengthening the Competitiveness of Japan\u2019s Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan\u2019s Highly Productive Firm","volume":"46","author":"Okuyama","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"ref_135","unstructured":"(2023, October 09). Mainichi Newspaper. Available online: https:\/\/mainichi.jp\/articles\/20220507\/ddm\/002\/010\/126000c."},{"key":"ref_136","unstructured":"(2023, October 09). NIKKEI Newspaper. Available online: https:\/\/www.nikkei.com\/article\/DGKKZO71685240Y1A500C2TL5000\/."},{"key":"ref_137","unstructured":"(2023, October 09). NIKKEI Newspaper. Available online: https:\/\/www.nikkei.com\/article\/DGXZQOUC026GZ0S3A800C2000000\/."},{"key":"ref_138","unstructured":"(2023, October 09). Ministry of Health, Labour and Welfare Homepage. Available online: https:\/\/www.cov19-vaccine.mhlw.go.jp\/qa\/0137.html."},{"key":"ref_139","unstructured":"(2023, October 09). Ministry of Health, Labour and Welfare News Release. Available online: https:\/\/www.mhlw.go.jp\/stf\/newpage_34457.html."},{"key":"ref_140","unstructured":"World Health Organization (2023, October 12). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1056\/NEJMp2202669","article-title":"Delivering Pandemic Vaccines in 100 Days\u2014What Will It Take?","volume":"387","author":"Saville","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/jpids\/piab108","article-title":"Metagenomic Next-Generation Sequencing (mNGS): SARS-CoV-2 as an Example of the Technology\u2019s Potential Pediatric Infectious Disease Applications","volume":"10","author":"Handel","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Quer, J., Colomer-Castell, S., Campos, C., Andr\u00e9s, C., Pi\u00f1ana, M., Cortese, M.F., Gonz\u00e1lez-S\u00e1nchez, A., Garcia-Cehic, D., Ib\u00e1\u00f1ez, M., and Pumarola, T. (2022). Next-Generation Sequencing for Confronting Virus Pandemics. Viruses, 14.","DOI":"10.3390\/v14030600"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/biot.201400390","article-title":"Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials","volume":"10","author":"Kallel","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJMp2027405","article-title":"Developing Safe and Effective Covid Vaccines\u2014Operation Warp Speed\u2019s Strategy and Approach","volume":"383","author":"Slaoui","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.plas.2021.100019","article-title":"Operation Warp Speed: Projects responding to the COVID-19 pandemic","volume":"2","author":"Winch","year":"2021","journal-title":"Proj. Leadersh. Soc."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.xphs.2020.11.010","article-title":"Warp-Speed COVID-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships","volume":"110","author":"Ho","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e068665","DOI":"10.1136\/bmj-2021-068665","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: Population based cohort study","volume":"375","author":"Husby","year":"2021","journal-title":"BMJ"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M21-3700","article-title":"Carditis After COVID-19 Vaccination with a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study","volume":"175","author":"Lai","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.lanepe.2021.100260","article-title":"Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England","volume":"13","author":"Andrews","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"de Gregorio, C., Colarusso, L., Calcaterra, G., Bassareo, P.P., Ieni, A., Mazzeo, A.T., Ferrazzo, G., Noto, A., Koniari, I., and Mehta, J.L. (2022). Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases. Vaccines, 10.","DOI":"10.3390\/vaccines10020232"},{"key":"ref_154","unstructured":"Global Entrepreneurship Monitor (2023, October 14). Entrepreneurial Behavior and Attitudes. Available online: https:\/\/gemconsortium.org\/economy-profiles\/japan-2."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/12\/1737\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:26Z","timestamp":1760131586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/12\/1737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":154,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["vaccines11121737"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11121737","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}